⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

May 15, 2018Liver CancerOpen Access

Hepatocellular Carcinoma with Irregular Rim-Like Arterial Phase Hyperenhancement: More Aggressive Pathologic Features

Hyungjin Rhee Chansik An Hyeyoung Kim Jeong Eun Yoo Young Nyun Park Myeong‐Jin Kim

View Full Paper

Ask AI

Bookmark

Share

Abstract

IRE-HCCs demonstrate aggressive histopathologic features, including more hypoxic and fibrotic tumor microenvironments and increased stemness, compared to non-IRE-HCCs. IRE might therefore serve as a noninvasive imaging biomarker for aggressive HCC.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Rhee et al. (2018) studied this question.

synapsesocial.com/papers/69de537f7ed287395e558817 https://doi.org/10.1159/000488540

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 related papers. Consider them for comparative context:

1Portal Vein Tumor Thrombus in Hepatocellular Carcinoma: An Immune Sanctuary Driving Immune Exclusion and Therapeutic ResistanceLiver Cancer · Sat,
2Asia-Pacific Transplant Oncology Symposium 2024: Expert Statements on the Current State and Future Direction of Hepatobiliary Surgical and Transplant OncologyLiver Cancer · Fri,
3Integrating Magnetic Resonance Imaging-Based Deep Learning and Radiomics to Predict Treatment Response in Hepatocellular Carcinoma Receiving Combined Systemic and Locoregional Therapies: A Multicenter StudyLiver Cancer · Tue,
4The Impact of Frailty in Hepatocellular CarcinomaLiver Cancer · Thu,
5Baseline Predictors, Prognostic Impact, and Risk Stratification of Early Progressive Disease on Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma: A Multicenter Real-World StudyLiver Cancer · Thu,

More from Liver Cancer

Targeting Plasmacytoid Dendritic Cell-Invariant Natural Killer T Axis through TLR7 Agonist to Enhance Anti-Tumor Immune Therapy in Residual Cancer after Incomplete Radiofrequency Ablation for Hepatocellular CarcinomaMon,
Deep Response as a Novel Efficacy Endpoint in Hepatocellular CarcinomaThu,
Outcomes by Comorbidities with Tremelimumab and Durvalumab in the Randomized, Controlled Phase 3 HIMALAYA Study in Unresectable Hepatocellular CarcinomaTue,
Exposure to poly- and perfluoroalkyl substances and risk of hepatocellular carcinoma in male patients with cirrhosis related to HCV infectionSat,
Selective Conventional Transarterial Chemoembolization Using a Glass Membrane Emulsification Device in Hepatocellular Carcinoma: Multicenter Clinical Trial in JapanFri,